Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:HTGM

HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis

HTG Molecular Diagnostics logo

About HTG Molecular Diagnostics Stock (NASDAQ:HTGM)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$5.01
$6.80
52-Week Range
N/A
Volume
773,040 shs
Average Volume
294,806 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Receive HTGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

HTGM Stock News Headlines

HTGMQ HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics Inc HTGMQ
Blackrock’s Sending THIS Crypto Higher on Purpose
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
HTG Molecular Diagnostics Inc (HTGMQ)
See More Headlines

HTGM Stock Analysis - Frequently Asked Questions

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its quarterly earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.60). The medical research company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $2.90 million. HTG Molecular Diagnostics had a positive trailing twelve-month return on equity of 45.52% and a negative net margin of 324.25%.

HTG Molecular Diagnostics (HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that HTG Molecular Diagnostics investors own include Sangamo Therapeutics (SGMO), Idera Pharmaceuticals (IDRA), NightHawk Biosciences (NHWK), Abeona Therapeutics (ABEO), Exelixis (EXEL), Bionano Genomics (BNGO) and Adamis Pharmaceuticals (ADMP).

Company Calendar

Last Earnings
11/10/2021
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:HTGM
Employees
84
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,590,000.00
Net Margins
-324.25%
Pretax Margin
-324.05%

Debt

Sales & Book Value

Annual Sales
$6.37 million
Price / Cash Flow
N/A
Book Value
$2.44 per share
Price / Book
N/A

Miscellaneous

Free Float
2,156,000
Optionable
Optionable
Beta
0.99

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:HTGM) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners